oseltamivir has been researched along with ritonavir in 19 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (15.79) | 24.3611 |
2020's | 16 (84.21) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Duan, Y; Zhou, C; Zhu, HL | 1 |
Gromiha, MM; Muralidharan, N; Sakthivel, R; Velmurugan, D | 1 |
Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM | 1 |
Daneshpazhooh, M; Isazade, A; Noormohammadpour, P; Soori, T | 1 |
Azadi, H; Darabi, E; Fathi, S; Ghanei, M; Ghazale, AH; Ghazvini, A; Izadi, M; Jafari, R; Movaseghi, F; Mozafari, A; Panahi, Y; Parsaei, MR; Ranjkesh, MH; Rezapour, M; Saadat, SH; Salesi, M; Vahedi, E; Zand, N | 1 |
Grundmark, B; Vidlin, SH; Watson, S; Zekarias, A | 1 |
Mamishi, S; Navaeian, A; Shabanian, R | 1 |
Akat, H; Laloglu, F; Orbak, Z | 1 |
Ahmadinejad, Z; Assari, R; Ayoobi Yazdi, N; Javanshayani, P; Khalili Afousi, H; Mazloomi, SH; Ziaee, V | 1 |
Gao, Q; Liu, D; Ma, D; Song, C; Tan, J; Xu, C; Yuan, Y | 1 |
Wen, S; Xu, X; Yadav, AK; Yu, L | 1 |
Arouche, TDS; Costa, FLP; Filho, TSA; JĂșnior, RNC; Martins, AY; Neto, AMJC; Ramalho, TC | 1 |
Aalipour, MA; Darazam, IA; Ghorbani, F; Pakdaman, H; Ramezani, M; Sagharichi, M; Simani, L | 1 |
Anedda, L; Bianchini, L; Cuzzolin, L; Fanos, V; Finco, G; Marcialis, MA | 1 |
Bartelt-Hunt, SL; Chen, C; Xu, X; Zhang, Y; Zhu, R; Zou, H | 1 |
4 review(s) available for oseltamivir and ritonavir
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunoglobulins; Immunologic Factors; Indoles; Lopinavir; Oseltamivir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Withholding Treatment | 2020 |
Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Chloroquine; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Oseltamivir; Purines; Pyrazines; Pyrazoles; Ribavirin; Ritonavir; Sulfonamides; Thiazoles | 2021 |
What if COVID-19 affects the child: which weapons and how to use them.
Topics: Adenosine Monophosphate; Adolescent; Age Factors; Alanine; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Carrier State; Child; Child, Preschool; Chloroquine; Continuous Renal Replacement Therapy; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Extracorporeal Membrane Oxygenation; Glucocorticoids; Humans; Hydroxychloroquine; Immunization, Passive; Immunoglobulins, Intravenous; Immunologic Factors; Infant; Infant, Newborn; Interferon-alpha; Lopinavir; Oseltamivir; Receptors, Cell Surface; Respiration, Artificial; Ribavirin; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thrombosis | 2021 |
15 other study(ies) available for oseltamivir and ritonavir
Article | Year |
---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Advance of promising targets and agents against COVID-19 in China.
Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Cobicistat; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Dibenzothiepins; Drug Combinations; Drug Discovery; Drug Therapy, Combination; Emtricitabine; Humans; Hydroxychloroquine; Indoles; Lopinavir; Medicine, Chinese Traditional; Morpholines; Oseltamivir; Oxazines; Pandemics; Pneumonia, Viral; Pyrazines; Pyridines; Pyridones; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tenofovir; Thiepins; Triazines; Viral Nonstructural Proteins | 2020 |
Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Drug Combinations; Drug Repositioning; Humans; Lopinavir; Oseltamivir; Peptide Hydrolases; Ritonavir; SARS-CoV-2 | 2021 |
Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case report.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Deprescriptions; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Humans; Hypertension; Immunoglobulins, Intravenous; Immunologic Factors; Iran; Lopinavir; Male; Mycophenolic Acid; Oseltamivir; Pandemics; Pemphigoid, Benign Mucous Membrane; Pneumonia, Viral; Prednisolone; Ritonavir; Rituximab; SARS-CoV-2; Tomography, Spiral Computed | 2020 |
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
Topics: Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Iran; Length of Stay; Levofloxacin; Lopinavir; Male; Meropenem; Middle Aged; Naproxen; Oseltamivir; Pneumonia, Viral; Prednisolone; Retrospective Studies; Ritonavir; Treatment Outcome; Vancomycin | 2020 |
Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
Topics: Abdominal Pain; Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Chemical and Drug Induced Liver Injury; Chloroquine; COVID-19 Drug Treatment; Databases, Pharmaceutical; Diarrhea; Drug Combinations; Drug Eruptions; Drug Repositioning; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Male; Nausea; Oseltamivir; Ritonavir; Sex Distribution; Sex Factors; Vomiting | 2020 |
Acute aortic dissection in a patient with Williams syndrome infected by COVID-19.
Topics: Adolescent; Anti-Bacterial Agents; Antiviral Agents; Aortic Aneurysm; Aortic Dissection; Aortic Stenosis, Supravalvular; Aortitis; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Enzyme Inhibitors; Fatal Outcome; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Immunologic Factors; Lopinavir; Male; Methylprednisolone; Oseltamivir; Recurrence; Ritonavir; SARS-CoV-2; Systemic Inflammatory Response Syndrome; Williams Syndrome | 2021 |
Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease.
Topics: Ampicillin; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; Azithromycin; Child; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; COVID-19 Serological Testing; Drug Combinations; Enoxaparin; Humans; Hydroxychloroquine; Hypoxia; Immunoglobulins, Intravenous; Immunologic Factors; Lopinavir; Lung; Male; Mucocutaneous Lymph Node Syndrome; Oseltamivir; Oxygen Inhalation Therapy; Ritonavir; Sulbactam; Tomography, X-Ray Computed | 2021 |
COVID-19 pandemic and biological therapy in rheumatologic disorders: how to deal with?
Topics: Adalimumab; Adult; Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Azathioprine; Betacoronavirus; Biological Therapy; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Combinations; Drug Therapy, Combination; Humans; Lopinavir; Male; Methotrexate; Oseltamivir; Pandemics; Pneumonia, Viral; Prednisolone; Ritonavir; SARS-CoV-2 | 2020 |
A retrospective comparison of drugs against COVID-19.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Viral; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Humans; Hydroxychloroquine; Immunoglobulin G; Immunoglobulin M; Indoles; Length of Stay; Lopinavir; Male; Middle Aged; Oseltamivir; Retrospective Studies; Ritonavir; SARS-CoV-2; Young Adult | 2021 |
Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
Topics: Azithromycin; Coronavirus 3C Proteases; COVID-19; Heparin; Humans; Ivermectin; Lopinavir; Molecular Docking Simulation; Oseltamivir; Ritonavir; SARS-CoV-2 | 2021 |
Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.
Topics: Adult; Aged; Antiviral Agents; Cough; COVID-19; COVID-19 Drug Treatment; Dementia; Drug Combinations; Dyspnea; Fatigue Syndrome, Chronic; Female; Fever; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Oseltamivir; Research Design; Ritonavir; SARS-CoV-2; Severity of Illness Index; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Survivors | 2021 |
COVID-19 related antiviral drugs are less adsorbable on sediment under alkaline and high cation conditions.
Topics: Adsorption; Antiviral Agents; COVID-19; Geologic Sediments; Humans; Oseltamivir; Pandemics; Ritonavir | 2023 |